Mary Ellen Molloy, Wade H Aaron, Manasi Barath, Mabel C Bush, Evan C Callihan, Kevin Carlin, Michael Cremin, Thomas Evans, Maria Gamez Guerrero, Golzar Hemmati, Avneel S Hundal, Llewelyn Lao, Payton Laurie, Bryan D Lemon, S Jack Lin, Jessica O'Rear, Purbasa Patnaik, Sony Sotelo Rocha, Linda Santiago, Kathryn L Strobel, Laura B Valenzuela, Chi-Heng Wu, Stephen Yu, Timothy Z Yu, Banmeet S Anand, Che-Leung Law, Liping L Sun, Holger Wesche, Richard J Austin
Delta-like ligand 3 (DLL3) is expressed in more than 70% of small cell lung cancers (SCLCs) and other neuroendocrine-derived tumor types. SCLC is highly aggressive and limited therapeutic options lead to poor prognosis for patients. HPN328 is a tri-specific T cell activating construct (TriTAC) consisting of three binding domains: a CD3 binder for T cell engagement, an albumin binder for half-life extension, and a DLL3 binder for tumor cell engagement. In vitro assays, rodent models and non-human primates were used to assess the activity of HPN328...
April 27, 2024: Molecular Cancer Therapeutics